Berry Genomics

Building 9, No.6 Courtyard
Jingshun East Road
Chaoyang District
Beijing
100015
China

Tel: 010-53259188

About Berry Genomics

Berry Genomics is a leading biotech company in China that develops and commercializes genomics-based integrated solutions for clinical applications, primarily in genetic testing and oncology testing. Berry pioneered non-invasive prenatal testing (NIPT) in China and today is the leading NIPT IVD product provider, as well as the leading provider of the test, in China. Like NIPT, the products and technologies under development at Berry Genomics will address unmet needs of other genetic diseases and cancer.
YEAR FOUNDED:
May 2010
LEADERSHIP:
CEO: Daixing Zhou, PhD

9 articles about Berry Genomics

PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China

1/11/2022

PacBio, a leading developer of high-quality, highly accurate sequencing platforms, and Berry Genomics, a leading company in clinical genomics and life science in China, announced a collaboration to provide PacBio long read sequencing technology to the Chinese clinical market.
Twist Bioscience and Berry Genomics to Offer New NGS Solution to Advance Research and Precision Medicine

2/22/2021

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that Berry Genomics, a leading commercial next-generation sequencing provider in China, will add Twist’s NGS target enrichment and library preparation tools to its offering.
Berry Genomics and Prenetics Establish JV to Enter China's Consumer Genetics Market

11/8/2018

Global genetics testing market expected to be worth USD 50-billion per annum by 20261
10x Genomics Announces Collaboration with Berry Genomics to Develop Next Generation Noninvasive Prenatal Testing (NIPT)

1/8/2018

The parties will collaborate to enable a new service offering for Berry Genomics.
Berry Genomics Completes $648 Million Reverse Merger In Shenzhen

8/31/2017
Week In Review: Beijing's Berry Genomics Valued At $619 Million In Reverse Merger

12/27/2016
Berry Genomics To Reverse-Merger At A $619 Million Valuation

12/27/2016
Beijing's Berry Genomics To Be Acquired By China Auto Parts Company

9/1/2016
BioNano Genomics And Berry Genomics To Co-Develop Next-Generation Mapping System For CFDA-Approved Clinical Use In China

8/18/2016